BioPorto Management

Management criteria checks 3/4

BioPorto's CEO is Peter Eriksen, appointed in Jan 2024, has a tenure of less than a year. directly owns 0.035% of the company’s shares, worth €22.92K. The average tenure of the management team and the board of directors is 0.9 years and 10.3 years respectively.

Key information

Peter Eriksen

Chief executive officer

kr.292.0k

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	0.03%
Management average tenure	less than a year
Board average tenure	10.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Peter Eriksen's remuneration changed compared to BioPorto's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	n/a	n/a	-kr.56m
Sep 30 2023	n/a	n/a	-kr.70m
Jun 30 2023	n/a	n/a	-kr.78m
Mar 31 2023	n/a	n/a	-kr.75m
Dec 31 2022	kr.292k	n/a	-kr.76m
Sep 30 2022	n/a	n/a	-kr.68m
Jun 30 2022	n/a	n/a	-kr.62m
Mar 31 2022	n/a	n/a	-kr.59m
Dec 31 2021	kr.3m	n/a	-kr.57m
Sep 30 2021	n/a	n/a	-kr.54m
Jun 30 2021	n/a	n/a	-kr.60m
Mar 31 2021	n/a	n/a	-kr.62m
Dec 31 2020	kr.7m	kr.3m	-kr.62m
Sep 30 2020	n/a	n/a	-kr.64m
Jun 30 2020	n/a	n/a	-kr.68m
Mar 31 2020	n/a	n/a	-kr.69m
Dec 31 2019	kr.6m	kr.3m	-kr.70m
Sep 30 2019	n/a	n/a	-kr.61m
Jun 30 2019	n/a	n/a	-kr.51m
Mar 31 2019	n/a	n/a	-kr.43m
Dec 31 2018	kr.4m	kr.3m	-kr.38m
Sep 30 2018	n/a	n/a	-kr.38m
Jun 30 2018	n/a	n/a	-kr.36m
Mar 31 2018	n/a	n/a	-kr.35m
Dec 31 2017	kr.5m	kr.3m	-kr.32m

Compensation vs Market: Peter's total compensation ($USD42.00K) is below average for companies of similar size in the German market ($USD396.12K).

Compensation vs Earnings: Peter's compensation has been consistent with company performance over the past year.

CEO

Peter Eriksen (63 yo)

less than a year

Tenure

kr.292,000

Compensation

Mr. Peter Morch Eriksen, BBA, serves as a Director of BioPorto A/S since November 15, 2021 and serves as its Interim CEO from January 09, 2024 until April 2024 and serves as its CEO since April 2024. He ha...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Peter Eriksen	CEO & Director	less than a year	kr.292.00k	0.035% DKK 22.9k
Lars Uttenthal	Chief Scientific Officer	no data	no data	no data
Gry Larsen	Executive VP & Chief Legal Officer	less than a year	no data	no data
Jennifer Zonderman	VP of Global Marketing & US Commercialization	5yrs	no data	no data
Nis Kruse	Executive VP of Strategic Partnerships and GM of EMEA & APAC	1.4yrs	no data	no data

0.9yrs

Average Tenure

Experienced Management: 2P4's management team is not considered experienced ( 0.9 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Peter Eriksen	CEO & Director	2.5yrs	kr.292.00k	0.035% DKK 22.9k
Donnie Hardison	Independent Vice Chairman of the Board	3.1yrs	kr.795.00k	no data
John McDonough	Independent Chairman of the Board	3.1yrs	kr.1.08m	0.046% DKK 30.4k
Claudio Ronco	Member of Scientific Advisory Board	10.3yrs	no data	no data
Jean-Louis Vincent	Chairman of the Scientific Advisory Board	10.3yrs	no data	no data
Ninfa Saunders	Independent Director	1.1yrs	kr.458.00k	no data
Michael Singer	Independent Director	4.8yrs	kr.674.00k	0.055% DKK 36.4k
Andrew Lewington	Vice Chairman of Scientific Advisory Board	10.3yrs	no data	no data
Laurent Jacob	Member of Scientific Advisory Board	10.3yrs	no data	no data
Michael Haase	Member of Scientific Advisory Board	10.3yrs	no data	no data
Hilde Geus	Member of Scientific Advisory Board	10.3yrs	no data	no data

10.3yrs

Average Tenure

63yo

Average Age

Experienced Board: 2P4's board of directors are seasoned and experienced ( 10.3 years average tenure).

BioPorto Management

Management criteria checks 3/4

Key information

Recent management updates

Bioporto A/S Appoints Gry Louise Husby Larsen as Chief Legal Officer and Member of the Executive Management Team, Effective as of April 15, 2024

Bioporto A/S Announces Tonni Bülow-Nielsennot to Stand for Election

BioPorto A/S Announces CEO Changes

BioPorto A/S, Annual General Meeting, Apr 30, 2024

BioPorto A/S Announces Resignation of Jan Leth Christensen as Board Member

Bioporto A/S Announces Resignation of Neil Goldman as CFO

Recent updates

Bioporto A/S Appoints Gry Louise Husby Larsen as Chief Legal Officer and Member of the Executive Management Team, Effective as of April 15, 2024

Bioporto A/S Announces Tonni Bülow-Nielsennot to Stand for Election

Full year 2023 earnings released: kr.0.16 loss per share (vs kr.0.24 loss in FY 2022)

BioPorto A/S Announces CEO Changes

BioPorto A/S to Report Nine Months, 2024 Results on Oct 30, 2024

BioPorto A/S, Annual General Meeting, Apr 30, 2024

BioPorto A/S Receives FDA 510(k) Clearance for NGAL Test in the United States

BioPorto A/S Announces Resignation of Jan Leth Christensen as Board Member

Bioporto A/S Provides Revenue Guidance for the Fiscal Year 2023

Bioporto A/S Announces Resignation of Neil Goldman as CFO

New major risk - Share price stability

BioPorto A/S announced that it has received $0.11 million in funding

Second quarter 2023 earnings released: kr.0.06 loss per share (vs kr.0.05 loss in 2Q 2022)

BioPorto A/S Maintains Earnings Guidance for the Year 2023

New minor risk - Shareholder dilution

High number of new and inexperienced directors

First quarter 2023 earnings released: kr.0.05 loss per share (vs kr.0.06 loss in 1Q 2022)

BioPorto A/S Maintains Financial Guidance for 2023

Full year 2022 earnings released: kr.0.24 loss per share (vs kr.0.21 loss in FY 2021)

BioPorto A/S to Report Q1, 2023 Results on May 10, 2023

BioPorto A/S Appoints Nis Kruse as EVP of Strategic Partnerships and Gm of EMEA & Apac

Less than half of directors are independent

Third quarter 2022 earnings released

BioPorto A/S Submits Application for Marketing Authorization of NGAL Test to the US Food and Drug Administration

BioPorto A/S Revises Earnings Guidance for the Year 2022

BioPorto A/S Revises Earnings Guidance for the Year 2022

Second quarter 2022 earnings released

BioPorto A/S Revises Earnings Guidance for the Year 2022

BioPorto A/S Achieves Targeted Enrollment in Clinical Study Supporting FDA De Novo Submission for The NGAL Test in the U.S

BioPorto A/S Appoints Dr. Prasad Devarajan as New Senior Medical Director

BioPorto A/S Maintains its Earnings Guidance for the Year 2022

Less than half of directors are independent

Full year 2021 earnings released: kr.0.21 loss per share (vs kr.0.30 loss in FY 2020)

BioPorto A/S Provides Earnings Guidance for the Full Year 2022

Third quarter 2021 earnings released: kr.0.04 loss per share (vs kr.0.087 loss in 3Q 2020)

Second quarter 2021 earnings released: kr.0.051 loss per share (vs kr.0.077 loss in 2Q 2020)

BioPorto A/S Maintains Earnings Guidance for the Year 2021

BioPorto A/S Provides Pipeline Update Regarding COVID-19 Test

First quarter 2021 earnings released: kr.0.06 loss per share (vs kr.0.088 loss in 1Q 2020)

BioPorto A/S Provides Earning Guidance for the Year 2021

Independent Vice Chairman Torben Nielsen has left the company

Independent Director has left the company

Full year 2020 earnings released: kr.0.30 loss per share (vs kr.0.41 loss in FY 2019)

Bioporto A/S Provides Earnings Guidance for the Year 2021

BioPorto Provides Pipeline Update

New 90-day high: €0.66

Revenue misses expectations

Third quarter 2020 earnings released: kr.0.09 loss per share

BioPorto A/S, Annual General Meeting, Apr 29, 2021

BioPorto A/S has completed a Follow-on Equity Offering in the amount of DKK 106.632762 million.

BioPorto A/S Plans Initial Clinical Evaluation of Grad-Based Test for Rapid Detection of COVID-19 Virus

New 90-day low - €0.28

Earnings released

New 90-day low - €0.30

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Board Members

Average Tenure

Average Age